Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil E Martin

Showing results (111-120 of 123) with videos related to

Pageof 13
Sort By:
Brachytherapy|February 27, 2016
Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costingNikhil G Thaker, Thomas J Pugh, Usama Mahmood, et al.
Cancer Medicine|March 24, 2022
Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathyXindi Zhang, Matthew R Trendowski, Emma Wilkinson, et al.
Journal of the National Cancer Institute|December 3, 2013
Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERGAndreas Pettersson, Rosina T Lis, Allison Meisner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell CarcinomaKent W Mouw, James M Cleary, Brendan Reardon, et al.
Eclinicalmedicine|April 13, 2026
Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from The Platinum Study: a multicentre cohort studyVictoria A Sanchez, Paul C Dinh, Patrick O Monahan, et al.
BJU International|August 16, 2014
Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancerDavid R Ziehr, Ming-Hui Chen, Danjie Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
SPINK1 protein expression and prostate cancer progressionRichard Flavin, Andreas Pettersson, Whitney K Hendrickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancerNeil E Martin, Thomas B Brunner, Krystina D Kiel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 28, 2012
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysisAndreas Pettersson, Rebecca E Graff, Scott R Bauer, et al.
European Urology|September 20, 2014
Defining a standard set of patient-centered outcomes for men with localized prostate cancerNeil E Martin, Laura Massey, Caleb Stowell, et al.
Pageof 13

Showing results (111-120 of 123) with videos related to

Sort By:
Pageof 13
Brachytherapy|February 27, 2016
Defining the value framework for prostate brachytherapy using patient-centered outcome metrics and time-driven activity-based costingNikhil G Thaker, Thomas J Pugh, Usama Mahmood, et al.
Cancer Medicine|March 24, 2022
Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus, and peripheral sensory neuropathyXindi Zhang, Matthew R Trendowski, Emma Wilkinson, et al.
Journal of the National Cancer Institute|December 3, 2013
Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERGAndreas Pettersson, Rosina T Lis, Allison Meisner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell CarcinomaKent W Mouw, James M Cleary, Brendan Reardon, et al.
Eclinicalmedicine|April 13, 2026
Impact of cisplatin dose, renal function, and other factors on audiometrically-assessed ototoxicity in more than 1400 adult-onset cancer survivors from The Platinum Study: a multicentre cohort studyVictoria A Sanchez, Paul C Dinh, Patrick O Monahan, et al.
BJU International|August 16, 2014
Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancerDavid R Ziehr, Ming-Hui Chen, Danjie Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
SPINK1 protein expression and prostate cancer progressionRichard Flavin, Andreas Pettersson, Whitney K Hendrickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 2004
A phase I trial of the dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778,123 and radiotherapy for locally advanced pancreatic cancerNeil E Martin, Thomas B Brunner, Krystina D Kiel, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 28, 2012
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysisAndreas Pettersson, Rebecca E Graff, Scott R Bauer, et al.
European Urology|September 20, 2014
Defining a standard set of patient-centered outcomes for men with localized prostate cancerNeil E Martin, Laura Massey, Caleb Stowell, et al.
Pageof 13